用机器学习提升非记忆型阿尔茨海默病的MRI诊断准确率
Machine learning-enhanced non-amnestic Alzheimer's disease diagnosis from MRI and clinical features
- 结合临床测试与全脑MRI特征,构建分类模型
- 对非典型患者诊断召回率从34%提升至77%
- 可帮助临床医生精准识别非记忆型患者
阿尔茨海默病(AD)通常通过淀粉样蛋白斑块和神经元缠结等生物标志物确诊,但其采集具有侵入性。多数诊断依赖认知测试与磁共振成像(MRI)评估海马萎缩。虽然此类方法对典型遗忘型AD(tAD)有高准确率,但大量非典型表现患者(atAD)常被误诊。本文提出一种机器学习方法,利用标准临床测试与MRI数据区分atAD与非AD认知障碍。基于1410名受试者(来自NACC、ADNI及一家私立数据集)的多组数据,实验涵盖海马体积与全脑多维MRI特征。最佳模型整合额外重要影像特征,显著优于仅使用海马体积的结果。通过Boruta统计方法识别并可视化关键脑区。该方法使NACC数据中atAD诊断召回率从52%升至69%,ADNI数据中从34%升至77%,同时保持高精确率。该方案为临床中仅用常规检查提升非典型患者诊断准确性提供了有效路径。
原文摘要 · Abstract (English)
Alzheimer's disease (AD), defined as an abnormal buildup of amyloid plaques and tau tangles in the brain can be diagnosed with high accuracy based on protein biomarkers via PET or CSF analysis. However, due to the invasive nature of biomarker collection, most AD diagnoses are made in memory clinics using cognitive tests and evaluation of hippocampal atrophy based on MRI. While clinical assessment and hippocampal volume show high diagnostic accuracy for amnestic or typical AD (tAD), a substantial subgroup of AD patients with atypical presentation (atAD) are routinely misdiagnosed. To improve diagnosis of atAD patients, we propose a machine learning approach to distinguish between atAD and non-AD cognitive impairment using clinical testing battery and MRI data collected as standard-of-care. We develop and evaluate our approach using 1410 subjects across four groups (273 tAD, 184 atAD, 235 non-AD, and 685 cognitively normal) collected from one private data set and two public data sets from the National Alzheimer's Coordinating Center (NACC) and the Alzheimer's Disease Neuroimaging Initiative (ADNI). We perform multiple atAD vs. non-AD classification experiments using clinical features and hippocampal volume as well as a comprehensive set of MRI features from across the brain. The best performance is achieved by incorporating additional important MRI features, which outperforms using hippocampal volume alone. Furthermore, we use the Boruta statistical approach to identify and visualize significant brain regions distinguishing between diagnostic groups. Our ML approach improves the percentage of correctly diagnosed atAD cases (the recall) from 52% to 69% for NACC and from 34% to 77% for ADNI, while achieving high precision. The proposed approach has important implications for improving diagnostic accuracy for non-amnestic atAD in clinical settings using only clinical testing battery and MRI.
Thank you to arXiv for use of its open access interoperability. PaperDance 不是 arXiv 官方产品;中文卡片由大模型生成,请以原文为准。